NCCN TRENDS DEMOGRAPHICS. Results: November 2013 NON-SMALL CELL LUNG CANCER. Distribution of Respondent Types (n = 835) Page 1

Transcription

1 NCCN TRENDS Results: November 2013 NCCN Trends is an analytics tool from the National Comprehensive Cancer Network (NCCN ) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the November 2013 NCCN Trends Survey, which focused on Non-Small Cell Lung Cancer. This survey was sent to U.S. and International users of NCCN.org. DEMOGRAPHICS Distribution of Respondent Types (n = 835) 11% Physician/Surgeon/Oncologist Nurse/Oncology Nurse or Clinical Nurse Specialist 75% 5% 3% Pharmacist Physician Assistant or Nurse Practitioner Other Clinician Note: Percentages may not total 100 because of rounding. Page 1

2 Q1. Do you treat patients with non-small cell lung cancer (NSCLC)? (n = 835) 70% Yes 30% No Q2. When do you test for mutations when treating patients with NSCLC? (n = 527) Prior to front line therapy 82% Prior to second or later line of therapy 18% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Page 2

3 Q3. Do you generally conduct a repeat biopsy at disease progression? (n = 524) Yes 27% No 73% 0% 10% 20% 30% 40% 50% 60% 70% 80% Q4. Are you aware of ImmunoHistoChemistry (IHC) testing for mesenchymal-epithelial transition (MET) amplification? (n = 509) Not at all familiar 35% Slightly familiar 32% Moderately familiar 23% Very familiar Extremely familiar 8% 2% 0% 10% 20% 30% 40% Page 3

4 Q5. How do you treat patients with driver mutations (EGFR or ALK) who develop resistance to first-line targeted therapy? (Please select all that apply) erlotinib (n=186) 45% crizotinib (n=21) 5% For EGFR mutation-positive patients afatinib (n=92) docetaxel (n=120) pemetrexed (n=145) cetuximab (n=43) best supportive care (n=65) clinical trial (n=104) other (n=29) 7% 11% 1 22% 25% 29% 35% erlotinib (n=23) For ALK mutation-positive patients crizotinib (n=155) afatinib (n=22) docetaxel (n=107) pemetrexed (n=109) cetuximab (n=9) best supportive care (n=55) clinical trial (n=119) 2% 14% 28% 28% 31% 40% other (n=38) 10% 0% 10% 20% 30% 40% 50% Page 4

5 NCCN TRENDS Results: November 2013 NCCN Trends is an analytics tool from the National Comprehensive Cancer Network (NCCN ) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends and clinician demographic data sets, allowing for greater insight into oncology practice patterns. To commission an NCCN Trends survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact: Christine MacCracken, MSHEd, BSN Senior Director, Business Insights maccracken@nccn.org National Comprehensive Cancer Network (NCCN ) The National Comprehensive Cancer Network (NCCN ), a not-for-profit alliance of 23 of the worldês leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. 275 Commerce Drive Suite 300 Fort Washington, PA, Telephone: Fax: NCCN.org - For Clinicians NCCN.org/patients - For Patients * All NCCN Trends survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes. Summary C-N Page 5